US-based NextGen Sciences has filed for intellectual property on a combination of protein biomarkers which could identify cognition changes in patients with early-stage dementia.
Go deeper with GlobalData
The firm has identified biomakers in cerebrospinal fluid which could aid decision-making on how to treat these patients.
NextGen Sciences CEO Barry McAleer said, “The biomarkers have the potential to assist in patient selection for clinical trials and to monitor the effectiveness of drugs in development. It gives us an immediate foothold in a critical healthcare market.”
Dementia affects around 36 million people around the world, but the number of people suffering from cognitive impairments, which are not severe enough to be classified as dementia, is significantly higher.
Biomarkers can be used to recognise the existence and the progression of the disease.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataMcAleer added, “It is clear to us all that real progress is needed to address the suffering and distress of the millions people affected by dementias. NextGen Sciences was established to help achieve this mission by exploiting the technological capabilities of its sister company, NextGen Sciences Inc.
“Filing for IP signals the start of our ongoing plans to secure maximum commercial returns on the discoveries we make.”
Caption: NextGen has identified biomakers in cerebrospinal fluid which could aid decision-making on how to treat patients with dementia.Credit: Dream Designs
